MiRTeL
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | JPY9.0m | Early VC | |
JPY10.0m | Convertible | ||
N/A | JPY190m | Early VC | |
N/A | JPY580m | Early VC | |
N/A | JPY460m | Late VC | |
Total Funding | €8.8m |
Related Content
Recent News about MiRTeL
EditMiRTeL Co., Ltd. is a pioneering company in the field of medical diagnostics, specializing in telomere and microRNA (MiR) testing to detect diseases at an early stage and prevent their progression. The company primarily serves medical professionals, patients, academic researchers, and members of the press. Operating in the healthcare diagnostics market, MiRTeL employs a business model that focuses on providing advanced diagnostic tests that can be used in clinical settings and research. Revenue is generated through the sale of these diagnostic tests and related services. The company's core products, telomere tests and MiR tests, are designed to identify potential health issues before they become severe, offering a proactive approach to healthcare.
Keywords: telomere tests, MiR tests, early detection, disease prevention, medical diagnostics, healthcare, clinical settings, research, innovative, Japan.